A Comparison of Microscopy and Enzyme Linked Immunosorbent Assay for Diagnosis of Giardia Lamblia in Children, Sohag
NCT ID: NCT06533696
Last Updated: 2024-08-01
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
94 participants
OBSERVATIONAL
2024-07-31
2025-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Impact of Anti-Giardia and Antihelmintic Treatment on Infant Growth in Bangladesh
NCT00607074
Study of Nitazoxanide in the Treatment of Amebiasis in Children
NCT00366730
Efficacy of Na-GST-1/Alhydrogel Hookworm Vaccine Assessed by Controlled Challenge Infection
NCT03172975
Nitazoxanide for the Treatment of Prolonged Diarrhea in Children
NCT01326338
Validating Egg-based Diagnostics and Molecular Markers for the Spread of Anthelmintic Resistance
NCT03465488
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
animals ( Dixon BR.,2021)
According to WHO reports in 2010, giardiasis is estimated to cause approximately 28.2 million cases of
diarrhea (WHO.,2015)
The prevalence of giardiasis is 2 to 5% in developed countries and 20 to 30% in developing countries in children (Luis et al.,2017)
The fecal-oral route is the main transmission mode of G. duodenalis . Drinking water, food and
vegetables contaminated by G. duodenalis cysts are the main sources of transmission ( Adam Rodney.,2021)
The common clinical manifestations of giardiasis include greasy diarrhea (steatorrhea), nausea,
vomiting, abdominal bloating, cramps, malabsorption and weight loss (Taghipour et al .,2022)
The detection and diagnosis of giardiasis present challenges for physicians, especially in regions distant
from high-prevalence areas where a substantial number of asymptomatic patients further complicate
prevalence determination. Symptoms, which closely mimic those of other parasitic diseases, can
confound clinicians, potentially leading to the prescription of ineffective remedies (Escobedo .et al .,2018)
Several different diagnostic systems have been described for the diagnosis of giardiasis: among them are
microscopic diagnosis, molecular methods, and immunoassays such as ELISA for the detection
of Giardia antigen or anti-Giardia antibodies, and Direct Fluorescence Antibody (DFA) test, which
detects antigens present on the cell wall of Giardia cysts ( Sadaka et al .,2015)
The early accurate diagnosis of giardiasis is important for the successful treatment and prevention of
diseases. The routine laboratory diagnosis is performed for the detection of trophozoites or cysts by
microscopic examination of at least three stool samples collected independently (.Uehlinger et al.,2017)
This diagnosis depends upon the times of sampling, patient compliance, application of concentration
methods, and the expertise of the technologists. Furthermore, in recent years, other methods, such as
ELIZA and molecular techniques are used mainly for diagnostic or research purposes. The sensitivity
and specificity of all diagnostic methods can be improved by including alternative diagnostic procedures
that are more rapid and reliable ( Kosack et al.,2017)
The recently licensed commercially available enzyme-linked immunosorbent assay (ELISA) kits are
found to be rapid and effective methods to diagnose Giardia infection in patients with gastrointestinal
symptomatology by detecting G. lamblia associated antigens in stool (Jahan et al.,2014)
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
OTHER
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
immunocompromised
immunocompromised cancer, renal failure and undernourished patients
No interventions assigned to this group
immunocompetent
exclude cancer, renal failure patients
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Sohag University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Arwa youssif Abdelsabor
demonstrator at medical parasitology department at faculty of medicine sohag
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Hanaa Ah El-Hady, Professor
Role: CONTACT
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Soh-Med-24-06-21MS
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.